Sciarretta S, Forte M, Frati G, Sadoshima J
Currently, formulary-exclusions from branded manufacturers have relegated generics of exenatide and of liraglutide (first-generation GLP-1s which have already gone generic) to the overlooked and unknown in spite of years of proven efficacy
The good news is that most sleep-related issues resolve as treatment continues, and many patients ultimately sleep better due to reduced sleep apnea and nighttime reflux as weight decreases
Serious adverse events were rare, and when occurred, they were not attributed to ALC
For example, if you paused at week 4 with 10 units per week, and are ready to resume at week 6, move up to 12 units per week when you return